What to do: If your bottle of ezetimibe 10 mg tablets contains any perindopril 4 mg tablets, or if you are unsure, return it to your pharmacy immediately. If you are unable to return your tablets to ...

FDA Approves New Labeling for VYTORIN to Include Data From SHARP Showing That VYTORIN Effectively Lowered LDL Cholesterol in These Patients, With Fewer Major Vascular Events in Patients Taking VYTORIN ...

For patients with homozygous familial hypercholesterolemia (HoFH) taking lomitapide, the dose should not exceed 10/20 mg/day (or 10/40 mg/day for patients who have previously taken simvastatin 80 ...

The results of 2 studies presented at the 2006 symposium of the International Society of Atherosclerosis in Rome, Italy, have demonstrated the benefit of adding the cholesterol absorption inhibitor ...

In this study, after a six- to eight-week washout period, patients with mixed hyperlipidemiaLDL cholesterol between 130 and 220 mg/dL (between 100 and 180 mg/dL for type 2 diabetics) and triglycerides ...

Please provide your email address to receive an email when new articles are posted on . A 20-mg daily dose of ezetimibe yielded significantly greater reductions in total and LDL cholesterol among ...

NEW ORLEANS, November 8, 2004 – Results from a new study showed that coadministration of ZETIA® (ezetimibe) and fenofibrate significantly reduced LDL ("bad") cholesterol (LDL-C), non-high density ...

(HealthDay News) — For patients with primary hypercholesterolemia, fixed-dose combination of ezetimibe plus rosuvastatin is more effective than rosuvastatin alone, according to a study published ...

Please provide your email address to receive an email when new articles are posted on . It is well known that HMG-CoA reductase inhibitors reduce LDL, a surrogate marker in atherosclerotic disease, as ...

Obicetrapib, a Lazarus-like cholesteryl ester transfer protein (CETP) inhibitor currently on its second life, checked another box in its development program with investigators showing the drug could ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response ...